No significant drug-related differences seen for clinical pain severity, thermal threshold or tolerance, general pain ...

Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...

A proprietary extended-release oral minoxidil, VDPHL01, shows superior efficacy and a consistent safety profile vs placebo for hair loss in men.

The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.

If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

New long-term data from Study 304 confirms lumateperone 42mg significantly delays time to relapse in clinically stable patients with schizophrenia.

Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

Treatment with three low-dose agents in single pill linked to lower incidence of recurrent stroke, major cardiovascular events in patients with hemorrhagic stroke ...

About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...